CURE’s gynecologic cancer page is an extensive resource of cancer information featuring the latest gynecologic cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on gynecologic cancer.
December 23rd 2024
As we near the end of 2024, CURE is looking back at the top FDA approval stories of the year.
Antibody-Drug Conjugate Is Tolerable, Active in CLDN6-Positive Solid Tumors Including Ovarian Cancer
September 15th 2024Treatment with the antibody-drug conjugate TORL-1-23 was safe and tolerable in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.